Agios Pharmaceuticals, Inc. (AGIO) 股票分析

公司概述

Agios Pharmaceuticals, Inc. operates as a biopharmaceutical entity dedicated to discovering and developing therapeutic medicines focused on cellular metabolism within the United States, with its current lead product, PYRUKYND (mitapivat), serving as an activator for wild-type and mutant pyruvate kinase enzymes intended for the treatment of hemolytic conditions. The company functions within the Healthcare sector and specifically the Biotechnology industry, a classification that denotes its reliance on intensive research and development cycles to bring novel biological treatments to market rather than traditional manufacturing-based revenue models. At present, the firm employs 539 individuals and maintains a market capitalization of $1.93B, while generating annual revenue of $54.03M. These financial figures indicate that the company operates as a mid-cap biotechnology entity with a significant market valuation relative to its current revenue stream, suggesting that the market places a high premium on its pipeline potential and future commercialization prospects rather than current profitability.

财务健康

The company reported trailing twelve-month revenue of $54.03M, yet recorded a net loss of $412,780,992 and an EBITDA of $-466,955,008, a disparity that reveals a cost structure heavily weighted toward research expenses, clinical trial costs, and operational overheads that significantly exceed current sales generation. Free cash flow stands at $-267,967,504, indicating that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity for distribution. The margin profile is characterized by a Gross Margin of 0.0%, an Operating Margin of -608.9%, and a Profit Margin of 0.0%, which collectively signify that the business is not yet achieving profitability at the gross or operational level, a common stage for early-phase biotechnology firms scaling production or preparing for market launch. On the liability side, the company holds $854.43M in cash against $40.21M in debt, resulting in a debt-to-equity ratio of 3.37, a metric that suggests a leveraged balance sheet structure where equity claims are diluted relative to debt obligations despite the substantial cash cushion. Liquidity is further supported by a Current Ratio of 11.46, a figure that indicates the company possesses ample short-term assets to cover its immediate liabilities without risk of insolvency. However, return metrics paint a picture of capital intensity; Return on Equity is -30.2% and Return on Assets is -19.9%, reflecting that management is currently deploying capital to expand the business rather than generating positive returns on the invested base.

估值评估

Valuation metrics for Agios Pharmaceuticals, Inc. present a complex picture due to the lack of earnings, with a Trailing Twelve Months P/E Ratio of N/A and a Forward P/E of -6.73, implying that the market is pricing the stock based on future earnings expectations that are currently negative and subject to significant uncertainty. The Price to Book ratio is recorded at 1.61, indicating that the market values the company at a 61% premium over its net asset book value, which often reflects intangible assets like intellectual property and clinical pipeline potential that are not captured on standard balance sheets. Alternative valuation multiples provide further context, with a Price to Sales ratio of 35.70 and an EV/EBITDA of -2.39, suggesting that investors are willing to pay a high multiple for each dollar of sales driven by the expectation of future product approvals and commercial success. Regarding trading range, the stock has a 52-Week High of $46.00 and a 52-Week Low of $22.24, positioning the current valuation somewhere within this volatility band depending on real-time market fluctuations. The Beta value is 0.79, which indicates that the stock's price volatility is lower than the broader market average, suggesting it may be less sensitive to general market swings compared to large-cap technology or finance stocks.

Growth & Income

Revenue growth for the trailing twelve months ended today shows a YoY increase of 86.1%, while Earnings Growth is listed as N/A due to the company's net loss position, highlighting that top-line expansion is currently the primary driver of shareholder value rather than earnings per share improvement. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, effectively allocating all available cash flow toward reinvestment in research, development, and operational scaling rather than returning capital to shareholders. This reinvestment strategy is typical for biotechnology firms in the growth phase, where retaining earnings is essential to fund the lengthy and capital-intensive processes required to bring new medicines to market. The overall growth and income profile is defined by rapid revenue expansion coupled with significant cash consumption, offering no current income yield but positioning the firm for potential future profitability upon successful product launches.